Annual report pursuant to Section 13 and 15(d)

Quarterly Financial Information (unaudited) (Parenthetical) (Details)

v3.10.0.1
Quarterly Financial Information (unaudited) (Parenthetical) (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2018
Jun. 30, 2018
Sep. 30, 2017
Jun. 30, 2017
Dec. 31, 2018
Dec. 31, 2017
Quarterly Financial Information [Line Items]            
Revenue recognized         $ 5,068 $ 52,428
Rezolute [Member] | License Agreement and Common Stock Purchase Agreement [Member]            
Quarterly Financial Information [Line Items]            
Revenue recognized   $ 1,800        
Janseen [Member] | License Agreement [Member]            
Quarterly Financial Information [Line Items]            
Revenue recognized $ 800          
Novartis International [Member] | License Agreement [Member]            
Quarterly Financial Information [Line Items]            
Revenue recognized     $ 35,400      
Milestone received under the collaboration agreement       $ 10,000   $ 10,000